Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years

BACKGROUND AND PURPOSE: The purpose of this study was to evaluate the outcomes of elderly patients (aged ≥75 years) with newly diagnosed glioblastoma (GBM), who were treated with hypofractionated radiotherapy comprising 45 Gy in 15 fractions combined with temozolomide (TMZ) or TMZ and bevacizumab (T...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Radiat Oncol
Hlavní autoři: Ohno, Makoto, Miyakita, Yasuji, Takahashi, Masamichi, Igaki, Hiroshi, Matsushita, Yuko, Ichimura, Koichi, Narita, Yoshitaka
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6852964/
https://ncbi.nlm.nih.gov/pubmed/31718669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13014-019-1389-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky